Last reviewed · How we verify

Zemplar (PARICALCITOL)

AbbVie · FDA-approved approved Small molecule Verified Quality 70/100

Zemplar works by activating the Vitamin D3 receptor, mimicking the natural effects of Vitamin D to regulate calcium levels and bone health.

Zemplar (Paricalcitol) is a Vitamin D Analog developed by Abbvie, targeting the Vitamin D3 receptor. It is a small molecule modality, FDA-approved in 1998 for treating Secondary Hyperparathyroidism due to Chronic Renal Failure. As an off-patent medication, it is available from multiple generic manufacturers. Key considerations include its 5.3-hour half-life and 72% bioavailability. Zemplar's commercial status allows for generic competition.

At a glance

Generic namePARICALCITOL
SponsorAbbVie
Drug classVitamin D2 Analog [EPC]
TargetVitamin D3 receptor
ModalitySmall molecule
Therapeutic areaNephrology
PhaseFDA-approved
First approval1998

Mechanism of action

Preclinical and in vitro studies have demonstrated that paricalcitols biological actions are mediated through binding of the vitamin receptor (VDR), which results in the selective activation of vitamin responsive pathways. Vitamin and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting PTH synthesis and secretion.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results